The Reagent Grade Tirnovetmab Market is experiencing steady growth as demand for high-purity monoclonal antibodies increases, pharmaceutical research applications expand, and diagnostic and clinical research use of tirnovetmab continues to rise. The market was valued at approximately USD 150 million in 2024 and is projected to reach around USD 300 million by 2033, growing at a CAGR of about...
